Open Access<p>Characteristics and Management of <em>TP53</em>-Mutated Diffuse Large B-Cell Lymphoma Patients</p>
Author(s) -
Yan Qin,
Shiyu Jiang,
Peng Liu,
Jianliang Yang,
Sheng Yang,
Xiaohong He,
Shengyu Zhou,
Lin Gui,
Jing Lin,
Xinhua Du,
Yuting Yi,
Yan Sun
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s269624
Subject(s) - medicine , regimen , diffuse large b cell lymphoma , refractory (planetary science) , gastroenterology , chop , stage (stratigraphy) , rituximab , lymphoma , oncology , surgery , progressive disease , chemotherapy , biology , paleontology , astrobiology
TP53 mutation is recognized as a negative prognostic factor for patients with diffuse large B-cell lymphoma (DLBCL). Here, we present the characteristics of TP53 mut DLBCL patients following investigation of the effect of a treatment approach on survival of TP53 mut DLBCL patients.